Here are 1-2 brief analogies for Liquidia (LQDA):

1. Liquidia is like the 'Dexcom for pulmonary arterial hypertension drugs,' aiming to make complex treatments much more patient-friendly through innovative delivery methods.

2. Think of Liquidia as a specialty pharmaceutical company that 'upgrades' existing critical medications by developing more convenient ways to administer them (e.g., a dry powder inhaler instead of an injection), and also sells generic versions of similar drugs.

• YUTREPIA: An inhaled dry powder formulation of treprostinil designed for the treatment of pulmonary arterial hypertension.
• Generic Treprostinil Injection: A distributed generic version of treprostinil in an injectable form.

Liquidia (LQDA) sells its pharmaceutical products primarily to major pharmaceutical wholesalers and specialty distributors. These companies then distribute the products to pharmacies, hospitals, and other healthcare providers.

The major customers of Liquidia are:

• AmerisourceBergen Corporation (ABC)
• Cardinal Health, Inc. (CAH)
• McKesson Corporation (MCK)

Lonza Ltd. (LONN)
Bespak Europe Ltd.
Piramal Pharma Solutions (PIRAMALPH)

Roger Jeffs, Ph.D. Chief Executive Officer

Roger Jeffs, Ph.D. joined Liquidia as CEO in 2022, having previously served on the company's Board of Directors since 2020. He is also the Vice-Chairman and Co-Founder of Kryia Therapeutics, a company focused on accelerating gene therapy development. Prior to Liquidia, Dr. Jeffs had an 18-year tenure at United Therapeutics Corporation, retiring as President & Co-CEO in 2016. During his time at United Therapeutics, he played a key role in the company's IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed commercial efforts that resulted in significant revenue growth. He previously held clinical development positions at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs has also served on the Boards of Directors for several other biopharmaceutical companies, including Axsome Therapeutics, Dova Pharmaceuticals, Sangamo Therapeutics, Axovant Gene Therapies, and Albireo Pharma.

Michael Kaseta Chief Operating Officer & Chief Financial Officer

Michael Kaseta joined Liquidia in 2020 as Chief Financial Officer and assumed the additional role of Chief Operating Officer in January 2023. His extensive background encompasses corporate finance, business strategy, and the commercialization of biopharma products across various company sizes. Before joining Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company, and previously held the CFO position at Aralez Pharmaceuticals Inc. He also spent eleven years at Sanofi, where he held various financial roles, ultimately becoming the Chief Financial Officer at Sanofi North America, Global Services, managing a $10 billion business covering numerous product launches and over a hundred products across eight therapeutic areas. Mr. Kaseta also serves on the Board of Directors of Bryn Pharma and Heron Therapeutics.

Rajeev Saggar, M.D. Chief Medical Officer

Dr. Rajeev Saggar joined Liquidia in 2022 as the company's Chief Medical Officer. He brings more than 20 years of experience as a practicing pulmonologist to his role, overseeing all aspects of research, clinical development, medical affairs, and regulatory affairs. Previously, Dr. Saggar served as Vice President of Clinical Development at Theravance Biopharma, where he had oversight of clinical development across its respiratory disease portfolio.

Scott Moomaw Chief Commercial Officer

Scott Moomaw joined Liquidia in 2020 as Chief Commercial Officer. He is a seasoned leader in biopharmaceuticals with considerable experience in product launches and developing commercial strategies and organizations. Mr. Moomaw co-founded RareGen, which was subsequently acquired by Liquidia, to commercialize Treprostinil Injection for pulmonary arterial hypertension (PAH). Before RareGen, he was Vice President of Marketing at Opko Health and United Therapeutics, where he was responsible for several treprostinil products, including Remodulin®, Tyvaso®, and Orenitram® for PAH.

Jason Adair Chief Business Officer

Jason Adair serves as the Chief Business Officer at Liquidia Corporation.

1. Patent Litigation with United Therapeutics

   Liquidia faces ongoing and significant patent litigation with United Therapeutics concerning its flagship product, YUTREPIA. United Therapeutics has filed multiple lawsuits alleging patent infringement and trade secret misappropriation related to YUTREPIA. This is identified as the "biggest near-term risk" and could lead to a court ruling that might halt or severely restrict the sale of YUTREPIA, which is the primary driver of Liquidia's new revenue. While Liquidia has expressed confidence in defending against these claims, the outcome could potentially impact market access or require royalty payments.

2. Intense Competition in the Pulmonary Arterial Hypertension (PAH) Market

   The market for pulmonary arterial hypertension (PAH) treatments is highly competitive. Liquidia's YUTREPIA competes with United Therapeutics' existing drug, Tyvaso DPI. Furthermore, other companies, such as Insmed, are developing new products that could enter the market in the coming years, potentially intensifying the competitive landscape and impacting Liquidia's market share and revenue growth.

3. Reliance on Third Parties for Manufacturing and Development

   Liquidia heavily relies on third-party contract research organizations (CROs) for clinical trials and contract manufacturing organizations (CMOs) for its manufacturing processes. This dependence introduces risks such as potential non-compliance with regulatory standards, which could lead to delays or the need for repeated studies. Any disruptions in the operations or performance of these third parties could significantly affect Liquidia's ability to develop, manufacture, and deliver its products to the market.

• Adverse outcomes in patent litigation with United Therapeutics, particularly concerning patents related to treprostinil and the '793 patent, which could delay or prevent the commercialization of YUTREPIA.
• The emergence and adoption of novel, highly efficacious therapies for pulmonary arterial hypertension (PAH) with new mechanisms of action, such as Merck's recently approved sotatercept (WINREVAIR), which could significantly alter the standard of care and reduce the market opportunity for existing and new treprostinil-based therapies, including YUTREPIA.

The addressable markets for Liquidia's main products are as follows:

YUTREPIA (inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension)

• The U.S. pulmonary arterial hypertension (PAH) market was valued at approximately USD 4 billion in 2024. It is projected to reach between USD 3.8 billion and USD 3.95 billion by 2030-2032.
• The global PAH market was valued at approximately USD 8.1 billion to USD 8.3 billion in 2024. It is expected to grow to between USD 13.2 billion and USD 13.9 billion by 2033-2034.

Generic Treprostinil Injection

• The global treprostinil drugs market, which includes injectable forms, is estimated at USD 14.3 billion in 2024 and is projected to reach USD 26.5 billion by 2032.
• The U.S. market for treprostinil drugs accounts for approximately 22.5% of the global market. Based on the 2024 global market size, the U.S. addressable market for treprostinil drugs is estimated at approximately USD 3.22 billion.

Here are 3-5 expected drivers of future revenue growth for Liquidia (LQDA) over the next 2-3 years:

1. Increased Adoption and Market Share Expansion of YUTREPIA: Liquidia's primary revenue driver is the continued rapid adoption and expansion of market share for YUTREPIA, its inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has demonstrated strong early commercial traction, capturing all market revenue growth in the inhaled treprostinil segment in Q4 2025, increasing its share from 10% to 17%. Management has reiterated a clear trajectory toward a $1.0 billion annual revenue target for YUTREPIA by 2027, with analysts projecting sales to reach $1.7 billion to $2 billion.
2. Expansion of YUTREPIA into New Indications: Liquidia plans to initiate new clinical studies to support the expansion of YUTREPIA into additional disease areas. These include systemic sclerosis-associated Raynaud's phenomenon and pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), representing opportunities to broaden the addressable patient population and generate new revenue streams.
3. Patient Transition from Oral and Other Inhaled Therapies to YUTREPIA: A significant driver of growth is the observed willingness of physicians to transition patients from existing oral and other inhaled prostacyclin therapies to YUTREPIA due to its differentiated product profile, deep-lung delivery, low-effort device, and wide dose range. Liquidia intends to initiate studies specifically aimed at facilitating this transition, which could further accelerate patient uptake and revenue growth.
4. Advancement of Pipeline Product L606: Liquidia is progressing its pipeline candidate, L606, an investigational extended-release formulation of treprostinil, into pivotal trials. While direct revenue generation from L606 may extend beyond the immediate 2-3 year timeframe, its advancement through clinical development bolsters the company's long-term growth prospects and can enhance investor confidence, supporting the overall valuation and strategic flexibility. The promising Phase 3 data for L606 suggests a favorable tolerability profile, further strengthening its potential.

Share Issuance

• In September 2024, Liquidia completed a public offering and a concurrent private placement, generating approximately $67.5 million in total gross proceeds. This involved the issuance of 6,460,674 shares in the public offering and 1,123,595 shares in a private placement, both priced at $8.90 per share.

Inbound Investments

• Liquidia entered into a fifth amendment to its Revenue Interest Financing Agreement (RIFA) with HealthCare Royalty (HCRx) in September 2024, securing an additional $32.5 million. This amendment completed HCRx's total non-dilutive capital investment of $100 million under the RIFA.

Capital Expenditures

• Liquidia Corporation invested $4.3 million in capital expenditures during fiscal year 2025.
• These capital expenditures are primarily focused on funding long-term assets, infrastructure, ongoing commercial development of YUTREPIA, and continued development of other clinical trials.